Health IT Firm CareDx To Acquire OTTR To Enable EMR Integrations At Transplant Centers

Healthcare News

Health_IT-Firm-CareDx-To-Acquire-OTTR-To-Enable-EMR-Integrations-At-Transplant-Centers Health IT Firm CareDx To Acquire OTTR To Enable EMR Integrations At Transplant CentersCareDx, Inc., a transplant diagnostics company, has agreed to purchase a provider of organ transplant patient tracking software, OTTR Complete Transplant Management (OTTR). For this acquisition, CareDx, as reports noted, will pay around USD16 million and intends to fund the transaction with cash on hand. The transaction is anticipated to close in May this year. Seated in Nebraska, OTTR offers comprehensive healthcare software solutions in organ transplant patient tracking that improve patient care through workflow management to cut down the costs. The company also provides solutions for transplant patient management, which are currently utilized in more than 60 leading transplant centers in the United States.

On this acquisition, CareDx CEO Peter Maag stated that CareDx and OTTR are very aligned in their dedication to improving outcomes for transplant patients. The integration of OTTR solutions into transplant center, EMR systems will simplify the logistics of ordering AlloSure or AlloMap testing for patients. Maag further added that this acquisition marks the beginning of CareDx’s leadership in transplant artificial intelligence as we integrate surveillance management tools and provide a solution for individualized patient outcomes. OTTR’s solutions allow integration with Electronic Medical Records (EMR) systems, including Cerner and Epic, offering patient surveillance management tools and outcomes data to transplant centers. As a molecular diagnostics-based company, CareDx applies modern genomics technologies to the development of molecular diagnostic assays that decode a patient’s immune status into clinically actionable information.

Based in Brisbane, CA, CareDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The in-house molecular expression technology is leverage by CareDx to develop AlloMap testing for heart transplant patient management. The application of gene expression testing to other diseases that entail the activity of the immune system like autoimmune and chronic inflammatory diseases is also being explored.